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MutantThe cross-species transmission of retroviruses is limited by host restriction factors that exhibit inter-species
diversity. For example, the TRIM5α proteins of OldWorld monkeys block the early, post-entry steps in human
immunodeﬁciency virus (HIV-1) infection. We adapted an HIV-1 isolate to replicate in cells expressing
TRIM5αrh from rhesus monkeys, an Old World species. A single amino acid change in the cyclophilin-binding
loop of the HIV-1 capsid protein allowed virus replication in cells expressing TRIM5αrh. The capsid of the
escape virus exhibited a reduced afﬁnity for TRIM5αrh, but retained the ability to bind cyclophilin A efﬁciently.
Thus, a preferred HIV-1 escape pathway involves decreased binding to TRIM5α, a capsid-destabilizing factor,
and retention of binding to cyclophilin A, a capsid-stabilizing factor.e, 44 Binney Street, CLS 1010,
J. Sodroski).
l rights reserved.© 2010 Elsevier Inc. All rights reserved.Introduction
Human immunodeﬁciency virus (HIV-1), the major cause of
acquired immunodeﬁciency syndrome (AIDS) in humans, arose as a
result of cross-species transmission of related viruses in chimpanzees
and gorillas (Hahn et al., 2000; Keele et al., 2006; Sharp et al., 2005;
Van Heuverswyn et al., 2006; Van Heuverswyn and Peeters, 2007).
These simian immunodeﬁciency viruses (SIVs) in apes are thought to
have been acquired from African monkeys, many species of which are
endemically infected by particular SIVs (Heeney et al., 2006; Van
Heuverswyn and Peeters, 2007). In establishing infections in new
species, the primate immunodeﬁciency viruses have encountered and
adapted to a variety of host restriction factors that exhibit lineage-
related differences in viral speciﬁcity. Appreciation of these restriction
factors is relevant not only to natural cross-species transmission of
viruses, but also to attempts to establish animal models of HIV-1
infection in humans.
Current animal models for HIV-1 infection are based on the
infection of macaques with SIV or simian-immunodeﬁciency virus
(SHIV) chimeras (Ambrose et al., 2007; Li et al., 1995). In the cells of
Old World monkeys, HIV-1 encounters three main blocks: TRIM5α,
APOBEC3 and BST2 (Mariani et al., 2003; McNatt et al., 2009; Stremlau
et al., 2004). After HIV-1 entry, the cytoplasmic factor TRIM5α
recognizes the incoming capsid and prematurely accelerates the
uncoating of the retroviral capsid, compromising virus infectivity(Stremlau et al., 2006a). APOBEC3G and APOBEC3F are cellular
cytidine deaminases that can be incorporated into newly produced
virions and block virus replication by various mechanisms, including
hypermutation of viral cDNA (Bishop et al., 2008; Lecossier et al.,
2003; Mbisa et al., 2007). The HIV-1 and SIV Vif proteins can inhibit
virion incorporation of APOBEC3G/F from some species by promoting
proteasome-mediated degradation (Yu et al., 2003). BST2 tethers
budding viral particles to the infected cell surface, blocking their
release (Neil et al., 2008; Van Damme et al., 2008). The HIV-1 Vpu
protein counters the impact of BST2 on virus release (Neil et al., 2008;
Van Damme et al., 2008). Overcoming these blocks may allow the
development of macaque models of infection with HIV-1-like viruses.
Recently, two groups have generated HIV-1/SIV chimeras composed
of about 90% HIV-1 sequences that efﬁciently infect macaque cells
(Hatziioannou et al., 2006; Kamada et al., 2006). These monkey-tropic
HIV-1 derivatives encode the SIVmac239 Vif protein and either a short
7-amino acid segment of the SIV capsid corresponding to the HIV-1
cyclophilin A-binding loop or the whole capsid of SIVmac.
In the present work, we adapted an HIV-1 isolate to replicate in
HeLa-CD4 cells expressing TRIM5αrh.
Results
Adaptation of HIV-1 to cells expressing rhesus monkey TRIM5α
To generate an HIV-1 variant resistant to rhesus monkey TRIM5α,
we employed an approach that was previously used to adapt HIV-1 to
replicate in CD4-negative, CCR5-expressing cells (Kolchinsky et al.,
1999) or in cells expressing CD4 and CXCR4 from commonmarmosets
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by transfection of an infectious proviral molecular clone into 293T
cells, and the resulting virus was passaged on HeLa cells expressing
CD4. HeLa cells naturally express CXCR4, the coreceptor utilized by
the NL4-3 envelope glycoproteins (Feng et al., 1996). This viral
stock was used to infect a culture of HeLa-CD4 cells in which 50% of
the cells expressed TRIM5αrh. Viral replication was determined by
measuring reverse transcriptase (RT) activity in the supernatant
of the cultures every 2–3 days. Viral supernatants derived from this
culture at the peak of RT activity were used to infect cultures of
HeLa-CD4 cells with 75% of cells expressing TRIM5αrh. This process
was repeated with cultures consisting of 90% and then 100% HeLa-CD4
cells expressing TRIM5αrh. In this way, viruses that demonstrated
the ability to replicate in cultures of 100% HeLa-CD4-TRIM5αrh cells
were obtained.
The gag and pol sequences of the adapted viruses were
examined by PCR ampliﬁcation of the genomic DNA of infected
cells extracted on the day when the supernatant RT activity reached
a maximum. The Gag, Pro, RT and RNaseH amino acid changes
observed in the adapted HIV-1NL4-3 variants are summarized in
Table 1. After the ﬁrst passage of the virus in cultures of 100% HeLa-
CD4-TRIM5αrh cells, all of the sequenced proviral clones exhibited a
mutation that converted valine 86 in the capsid protein to
methionine. This change (V86M) was also present in all the
proviral clones derived after additional passages of virus in cultures
of 100% HeLa-CD4-TRIM5αrh cells (see Table 1). The V86M change
has not been observed in natural HIV-1 strains (Kuiken et al., 2008),
suggesting that its appearance may result from speciﬁc selective
pressure associated with these experiments. A number of clones
contained additional changes that affected HIV-1 proteins other
than the capsid; however, most of these changes were found only
in single clones and none were maintained between the ﬁrst and
third passages of virus in the 100% HeLa-CD4-TRIM5αrh cultures.
Therefore, we focused on assessing the contribution of the V86M
change in the capsid protein to virus adaptation to TRIM5αrh.Table 1
Amino acid changes in the HIV-1NL4-3 gag and pol protein products following adaptation
to TRIM5αrh-expressing cells.a
Region Predicted amino acid
change
Presence of amino acid change in
1st passage
Clone
1
Clone
2
Clone
3
Clone
4
Clone
5
MA R20W X X
CA V86M X X X X X
Protease V11I X X
Protease M46I X
RT G196R X
RT E296K X
RNase V119I X
Region Predicted amino acid
change
Presence of amino acid change in
3rd passage
Clone
1
Clone
2
Clone
3
Clone
4
Clone
5
MA S126R X
CA V86M X X X X X
p6 F17I X
RT R206G X
RT A26T X
RNase D48N X
Integrase G70E X
a HIV-1NL4-3 viruses adapted to cultures of 100% HeLa-CD4-TRIM5αrh cells were
passaged additional times in these cells. The gag and pol genes of the proviruses from
the ﬁrst and third passages were ampliﬁed by PCR and cloned. The differences between
the predicted amino acids of the proteins of the adapted virus and those of the parental
HIV-1NL4-3 are shown.Characterization of the sensitivity of the HIV-1 V86M capsid
mutant to TRIM5αrh
Valine 86 is located in the cyclophilin A-binding loop of the HIV-1
capsid protein (Fig. 1A and B). Changes in the cyclophilin-binding loop
of the capsid have been previously shown to reduce HIV-1 sensitivity to
early-acting restriction factors in Old World monkey and owl monkey
cells (Chatterji et al., 2005; Gatanaga et al., 2006; Hatziioannou et al.,
2004; Ikeda et al., 2004; Kootstra et al., 2003, 2007; Nagao et al., 2009;
Owens et al., 2004). Of note, some of these changes involve the histidine
87 residue, which is adjacent to valine 86. Other changes involving
glycine 89 and proline 90 in the capsid cyclophilin-binding loop disrupt
the binding of cyclophilin A, which in some cases appears to potentiate
TRIM5αrh restriction of HIV-1 (Berthoux et al., 2005; Stremlau et al.,
2006b; Towers et al., 2003). We compared the effect of some of these
capsid changes with that of the V86M change on HIV-1 infection of
HeLa-CD4cells expressingTRIM5αrh. The effect of the capsid changes on
the replication of theHIV-1NL4-KB9 SEMQviruswas examined; the SEMQ
alteration in Vif is reported to overcome partially the replication block
conferredby rhesusmonkeyAPOBEC3G(Schrofelbauer et al., 2006). The
replication of the HIV-1NL4-KB9 SEMQ virus with the wild-type and
mutant capsids in HeLa-CD4-TRIM5αrh cells is shown in Fig. 2A. HIV-1
viruses containing the V86M or H87Q changes replicated efﬁciently
in these cells, reaching a peak of RT activity around days 15 and 19,
respectively. Beginning at approximately 19 days after infection,
RT activity was detected in the culture infected by the P90A mutant;
the RT activity in this culture reached a peak around day 33 post-
infection. Reverse transcriptase remained at background levels in
cultures inoculated with HIV-1NL4-KB9 SEMQ bearing the wild-type
capsids, even after 40 days in culture. In parallel, as a control, we
incubated this panel of viruses with Cf2Th cells stably expressing
human CD4 and CXCR4, but not TRIM5αrh. All the viruses replicated
efﬁciently in this cell line (Fig. 2B); the delay in replication of the
P90Amutant is consistent with the consequences of poor cyclophilin
A binding. These results demonstrate that the V86M capsid change
associated with virus passage in TRIM5αrh-expressing cells increases
the resistance of HIV-1 to the inhibitory effects of rhesus monkey
TRIM5α.
To examine whether the combination of the V86M or the H87Q
capsid changes with the VifSEMQ changes were sufﬁcient to allow HIV-
1 to replicate in rhesus macaque cells, we infected the 221-89
lymphoid cell line (Alexander et al., 1997) and rhesus monkey PBMCs
with HIV-1NL4-KB9 viruses containing these changes. Virus replication
was not detected in this rhesus T cell line nor in rhesus macaque
PBMCs (data not shown). This result suggests that additional changes
in HIV-1 are needed to allow efﬁcient replication in rhesus monkey
cells. This result was not unexpected, given the existence of rhesus
monkey restriction factors such as BST2 (tetherin) that operate during
the late phase of HIV-1 replication (Neil et al., 2008; Van Damme et al.,
2008). Rhesus monkey BST2 is not effectively countered by the HIV-1
Vpu protein (Jia et al., 2009; McNatt et al., 2009). Moreover, the SEMQ
changes in the Vif protein may be insufﬁcient to allow HIV-1 to
overcome APOBEC3G restriction and to replicate in the cells of Old
World monkeys (Hatcho et al., 2008; Kamada et al., 2009).
To examine the ability of V86M and other capsid variants to escape
speciﬁcally from the early restriction imposed by TRIM5αrh, we infected
cells with recombinant HIV-1 vectors containing the capsid changes.
These viruses were pseudotyped with the vesicular stomatitis virus
(VSV)Gglycoprotein,whichallows entry into awide rangeof vertebrate
cells. The recombinant viruses express either green ﬂuorescent protein
(GFP) or luciferase. The V86M change in the capsid protein allowed
more efﬁcient single-round infection of HeLa-CD4-TRIM5αrh cells than
was observed for the wild-type recombinant HIV-1 vector (Fig. 2C).
Because the R20W change in thematrix protein appeared in two clones
duringanearly passage of thevirus inHeLa-CD4-TRIM5αrh cells,we also
tested the contribution of this change. An HIV-1 vector containing the
Fig. 1. Thecyclophilin A-binding loopof theHIV-1 capsid protein. (A) The ribbon structureof a cyclophilin A-HIV-1 p24 capsidprotein complex is shown (Gamble et al., 1996). Thecyclophilin
A-binding loop is colored yellow. Thecomplex isoriented so that, in an assembled capsid, the exposed surfaceof the capsidprotein faces the viewer. (B) TheHIV-1 capsidprotein is oriented as
in (A), with the side chains of the amino acid residues relevant to this study colored according to the following key: valine 86 (red), other residues in the cyclophilin A-binding loop that have
been shown to inﬂuence HIV-1 sensitivity to rhesus monkey restriction (green) (Owens et al., 2004), and residues that directly contact cyclophilin A (magenta). (C) Three HIV-1 capsid
hexamers are shownas theyare related ina crystal lattice, approximating their relationship in anassembled capsid (Pornillos et al., 2009). Thesurfaceof theassembled capsid faces theviewer,
and the cyclophilin A-binding loops (yellow) andvaline 86 residues (red) are highlighted. The right panel provides a close-up of the region at the intersection of the three hexamers in the left
panel. The local 3-fold (triangle) and2-fold (ellipses) axes of symmetry are shown.Thecyclophilin A-binding loops at thedistal endof eachhexamer spoke are locatednear thedepressions on
the surface of the assembled capsid that track along the 2- and 3-fold axes of pseudosymmetry.
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capsid infected the HeLa-CD4-TRIM5αrh cells similarly to the viruswith
only the V86M change. All three recombinant viruses infected the
control HeLa-CD4 cells efﬁciently (Fig. 2D).We conclude that the V86M
change in the capsid protein confers an advantage during the infection
of HeLa cells expressing TRIM5αrh.
HeLa cells express human TRIM5α, which only minimally inhibits
HIV-1 infection (Stremlau et al., 2004); the presence of human TRIM5α
might inﬂuence the potency with which TRIM5αrh restricts HIV-1
infection. Therefore, we used single-round, luciferase-expressing HIV-1
to examine the contribution of the V86M capsid change to the early
phase of infection of another cell type expressing TRIM5αrh. We
compared the infectivity of recombinant HIV-1 with the V86M change,
or with different changes in the capsid previously reported to affect
sensitivity to TRIM5α restriction or cyclophilin A binding (Chatterji
et al., 2005; Gatanaga et al., 2006; Hatziioannou et al., 2004; Ikeda et al.,
2004; Kootstra et al., 2003, 2007; Owens et al., 2004; Towers et al.,
2003). CanineCf2Th cells,whichdonot express an endogenous TRIM5α
protein (Sawyer et al., 2007),were used as target cells; in addition to the
control cells transduced with the empty LPCX vector, we used Cf2Thcells expressing TRIM5αrh and Cf2Th cells expressing the owl monkey
TRIMCyp protein. The latter protein is expressed in the NewWorld owl
monkey lineage as a result of a retrotransposition that fuses the amino-
terminal part of TRIM5 with the cyclophilin A protein (Nisole et al.,
2004; Sayah et al., 2004). In control canine Cf2Th cells transduced with
an empty LPCX vector, all of the HIV-1 capsid mutants, with the
exception of H87Q, infected less efﬁciently than the wild-type HIV-1
(Fig. 3A). An HIV-1 vector (SCA) containing the SIVmac capsid (Owens
et al., 2003) also infected these control cells less efﬁciently than wild-
type HIV-1. In Cf2Th cells expressing TRIM5αrh, the SCA virus exhibited
a higher level of infectivity than wild-type HIV-1. The V86M and H87Q
HIV-1 variants also infected these cells slightly more efﬁciently than
wild-type HIV-1 (Fig. 3B). The G89A and P90A HIV-1 capsid mutants,
which are defective for cyclophilin A binding (Braaten et al., 1996;
Franke et al., 1994), infected the TRIM5αrh-expressing cells poorly. By
contrast, these HIV-1 variants, as well as SCA, infected Cf2Th cells
expressing owl monkey TRIMCyp muchmore efﬁciently than the other
viruses, including wild-type HIV-1 (Fig. 3C). This was expected, as
neither the SIVmac nor the G89A or P90A HIV-1 capsids bind TRIMCyp
(Hatziioannou et al., 2004; Sayah et al., 2004; Towers et al., 2003). These
Fig. 2. Replication of HIV-1 capsid mutants in HeLa-CD4 cells stably expressing TRIM5αrh. (A, B) HeLa-CD4 cells expressing TRIM5αrh (A) or control Cf2Th-CD4/CXCR4 cells
(B) were incubated with 30,000 RT units of the indicated HIV-1NL4-KB9 SEMQ variants for 14 h and then washed once with PBS. Every 3 or 4 days, cell supernatants were
removed and used for RT assays. Cells were then trypsinized, diluted 1/10 in fresh medium and replated. (C, D) Recombinant, single-round HIV-1 expressing GFP were
incubated with HeLa-CD4 cells expressing TRIM5αrh (C) or control HeLa-CD4 cells transduced with the empty LPCX vector (D). GFP expression was measured 48 h later.
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speciﬁcally advantageous during the infection of Cf2Th-TRIM5αrh cells.
We also examined the ability of these single-round recombinant
viruses to infect primary rhesus monkey lung (PRL) ﬁbroblasts, MK2D
rhesus macaque cells and the OMK owl monkey kidney cell line. The
PRL andMK2D cells express TRIM5αrh, whereas the OMK cells express
TRIMCyp from owl monkeys, a New World monkey species (Sayah
et al., 2004; Stremlau et al., 2004; Wilson et al., 2008). Wild-type HIV-
1 infection of PRL cells was nearly undetectable, whereas SCA infected
these cells very efﬁciently (Fig. 3D). The V86M and H87Q HIV-1
mutants and, to a slightly lesser extent, the G89A and P90A mutants,
infected the PRL cells more efﬁciently than wild-type HIV-1. In the
MK2D rhesus monkey cells, infection by wild-type HIV-1 and the
G89A and P90A mutants was much less efﬁcient than infection
mediated by the V86M and H87Q mutants. In the OMK cells from the
owlmonkey, only SCA and the G89A and P90AHIV-1mutants infected
efﬁciently. Thus, as was observed in the Cf2Th cells above, the V86M
and H87Q changes in the HIV-1 capsid confer a speciﬁc advantage
during the early phase of infection of cells expressing rhesus monkey
TRIM5α.
Competition of wild-type and mutant virus-like particles for
restriction factors
Previous studies have shown that the restriction of HIV-1 in Old
World monkey cells can be saturated by incubation of the cells with
enveloped virus-like particles (VLPs) (Cowan et al., 2002; Hatziioannou
et al., 2003; Munk et al., 2002). To test whether the HIV-1 capsid
mutants were able to compete for restriction factors in primary rhesus
monkey cells, we incubated PRL cells with thewild-type HIV-1 reportervirus encoding ﬁreﬂy luciferase along with wild-type or mutant VLPs.
The presence of wild-type HIV-1 VLPs increased the infectivity of the
HIV-1 reporter virus (Fig. 4), suggesting that these VLPs are able to
compete for the binding to restriction factors. The V86M, H87Q, G89A
and P90A mutant VLPs exhibited reduced ability to compete for
restriction factors in the PRL cells, compared with the wild-type HIV-1
VLPs. The YQ VLPs, which contain two changes in the HIV-1 capsid that
reduce susceptibility to Old World monkey TRIM5α without affecting
restriction factor binding (Owens et al. 2004), competed efﬁciently for
restricting activity. As expected, HIV-1 VLPs without envelope glyco-
proteins or the SCA VLPs, which have an SIVmac capsid in an HIV-1
background (Owens et al., 2003), did not compete for the PRL restriction
factor(s). The results suggest that all of the HIV-1 VLPs with changes in
the cyclophilin-binding loop interact less efﬁciently with restriction
factors following entry into PRL cells.
Capsid binding to cyclophilin A, TRIM5αrh and TRIMCyp
To determine the effects of the HIV-1 capsid changes on the
binding of cyclophilin A, we examined cyclophilin A incorporation
into HIV-1 VLPs that were produced in cyclophilin A-expressing cells.
Although the major effects of cyclophilin A incorporation are
manifested during the early phase of HIV-1 infection (Hatziioannou
et al., 2005), the level of cyclophilin A in the virions is a surrogate for
capsid-binding afﬁnity. We transfected 293T cells with plasmids
expressing the wild-type or mutant HIV-1 Gag-Pol proteins, the HA-
tagged human cyclophilin A and the HIV-1 Rev protein. As one control,
we used a chimeric HIV-1/SIVmac provirus (SCA) encoding the SIVmac
capsid (Owens et al., 2003). As a second control, a wild-type HIV-1
VLPwas produced in the absence of HA-tagged cyclophilin A. The VLPs
Fig. 3. Infectivity of HIV-1 capsid mutants in different cell lines. Target cells were infected with single-round recombinant reporter viruses expressing ﬁreﬂy luciferase. Forty-eight
hours after infection, cells were lysed and the luciferase activity was measured using an EG&G Berthold LB 96 V microplate luminometer. The target cells were: Cf2Th cells stably
transduced with the empty LPCX vector (A), Cf2Th cells stably expressing TRIM5αrh (B); Cf2Th cells stably expressing owl monkey TRIMCyp (C); primary rhesus monkey lung (PRL)
ﬁbroblasts (D), rhesus monkey kidney (MK2D) cells (E); and owl monkey kidney (OMK) cells (F). RLU, relative luciferase units.
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capsid antibodies (Fig. 5A and Table 2). The V86M, H87Q and YQ
mutant VLPs efﬁciently incorporated cyclophilin A, whereas the G89A
and P90Amutant VLPs incorporated only trace amounts of cyclophilin
A. The HIV-1/SIVmac chimera (SCA) with the SIVmac capsid did not
detectably incorporate cyclophilin A into VLPs. We conclude that the
V86M capsid mutant retains the ability to bind cyclophilin A
efﬁciently.
TRIM5α speciﬁcally recognizes assembled retroviral capsids rather
than individual capsid proteins (Dodding et al., 2005; Sebastian and
Luban, 2005). To investigate the ability of TRIM5αrh to recognize the
mutant HIV-1 capsids, we analyzed the binding of HA-tagged
TRIM5αrh to wild-type and mutant capsid–nucleocapsid (CA–NC)
complexes that had been assembled in vitro, as previously described
(Stremlau et al., 2006a). TRIM5αrh bound efﬁciently to the wild-type,
YQ, G89A and P90A CA–NC complexes (Fig. 5B and Table 2). In fact,
the binding of TRIM5αrh to the YQ CA–NC complexes was moreefﬁcient than to thewild-type CA–NC complexes. By contrast, TRIM5αrh
binding to the V86M and H87Q CA–NC complexes was signiﬁcantly
reduced compared to the binding observed for the wild-type CA–NC
complexes (Table 2). Thus, diminished binding of TRIM5αrh by the
V86MandH87Q capsids provides a natural explanation for the ability of
these mutants to escape TRIM5αrh restriction.
We also tested the binding of owl monkey TRIMCyp to the wild-
type and mutant CA–NC complexes (Fig. 5C and Table 2). TRIMCyp
bound efﬁciently to the wild-type, V86M and YQ CA–NC complexes,
and with an intermediate level of efﬁciency to the H87Q variant. In
agreement with their reduced afﬁnity for cyclophilin A, the G89A and
P90A CA–NC complexes did not detectably bind TRIMCyp.
Discussion
Selection of an HIV-1 variant for replication in cells expressing
TRIM5αrh allowed an assessment of the preferred viral solution to the
Fig. 4. Competition assay with HIV-1 VLPs. Target PRL cells were infected with 2,500 RT
units of the wild-type recombinant HIV-1 expressing luciferase in the presence of
100,000 RT units of virus-like particles (VLPs) lacking a reporter gene. The capsid
proteins of the VLPs were either wild-type HIV-1 (wt) or contained the indicated
changes. All VLPs were pseudotyped with the VSV G glycoprotein, except control VLPs
with wild-type HIV-1 capsids but with no added envelope glycoproteins (no Env).
Forty-eight hours after infection, cells were lysed and the luciferase activity was
measured.
Table 2
Interaction of ligands with HIV-1 capsid variants.
Capsid
variant
Relative cyclophilin A
incorporationa
Relative TRIM5αrh
bindingb
Relative TRIMCyp
bindingb
wt 1.00 1.00 1.00
V86M 0.84±0.39 0.05±0.05 0.88±0.32
H87Q 0.75±0.61 0.18±0.18 0.46±0.14
YQ 1.02±0.57 1.77±0.90 0.74 ±0.32
G89A 0.08±0.04 0.84±0.30 0.03±0.008
P90A 0.09±0.07 0.87±0.18 0.06±0.10
SCA 0.06±0.07 ND ND
a The incorporation of HA-tagged cyclophilin A into HIV-1 virus-like particles (VLPs)
was measured as described in Materials and Methods. The values for the mutant VLPs
were normalized to those observed for the wild-type (wt) VLP. Themeans and standard
deviations derived from three independent experiments are shown.
b The binding of TRIM5αrh and owl monkey TRIMCyp to HIV-1 CA–NC complexes
was measured as described in Materials andMethods. The values for the mutant CA–NC
complexes were normalized to those observed for the wild-type (wt) CA–NC complex.
The means and standard deviations derived from three independent experiments are
shown. ND=not determined.
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acid change, V86M, in the cyclophilin A-binding loop of the capsid
protein was sufﬁcient to allow efﬁcient HIV-1 replication in HeLa-CD4
cells expressing TRIM5αrh. Of note, changes in the cyclophilin A-
binding loop of capsid, including one change (V86Q) in valine 86,
were previously shown to confer improved HIV-1 infectivity in Old
World monkey target cells (Hatziioannou et al., 2004; Ikeda et al.,
2004; Kootstra et al., 2003, 2007; Nagao et al., 2009; Owens et al.,
2004). These changes involved valine 86, histidine 87, methionine 96
and arginine 100, residues that are located near the point of departure
of the cyclophilin A-binding loop from the main body of the capsid
protein (Fig. 1B). Because of this location, changes in these residues
have the potential to alter the conformation/orientation of the distal
cyclophilin A-binding loop. The impact of such alterations on the
structure of the capsid surface could be ampliﬁed by the location of
the cyclophilin A-binding loop at the end of the hexamer spoke,
proximal to 2-fold and three-fold axes of pseudosymmetry (Fig. 1C).
Our results suggest that the mechanism of escape of the V86M
mutant is a reduced interaction of the capsid with TRIM5αrh. Both the
V86M and the H87Q VLPs competed for restriction factors in PRL cells
less efﬁciently than wild-type HIV-1 VLPs. The TRIM5αrh protein in
cell lysates bound less to the V86M and H87Q capsid-nucleocapsid
complexes than to wild-type HIV-1 CA–NC complexes. PreviousFig. 5. Interaction of ligands with the HIV-1 capsid variants. (A) Cyclophilin A incorporation i
coexpressed FLAG-tagged cyclophilin A (CypA) were pelleted through a 20% sucrose cushio
and anti-FLAG antibodies. The incorporation of cyclophilin A into mutant VLPs, relative
representative experiment is shown. (B,C) The binding of TRIM5αrh or owl monkey TRIMC
measured as previously described (Stremlau et al., 2006a). The samples were analyzed by W
(Immunodiagnostics, Inc.) and an anti-HA antibody (3F10) conjugated to horseradish pero
relative to the binding to wt HIV-1 CA–NC complexes, is reported in Table 2. The results of a
capsid protein (Owens et al., 2004).studies have suggested that TRIM5α recognizes assembled capsid
structures rather than individual capsid proteins (Dodding et al.,
2005; Sebastian and Luban, 2005). Moreover, TRIM5α B-box 2
mutants that can dimerize but not form higher-order oligomers
exhibit reductions in capsid-binding ability and virus restriction
(Diaz-Griffero et al., 2009; Li and Sodroski, 2008). Thus, retrovirus
restriction apparently is mediated by an array of TRIM5α dimers that
must ﬁrst assemble on the surface of the viral capsid. In light of this
requirement, the potential of valine 86 and histidine 87 changes to
affect the conformation of the cyclophilin A-binding loop and thereby
to alter the boundaries of the two- or three-fold symmetric pockets on
the capsid surface is noteworthy. To gain avidity for the capsid,
TRIM5α dimers are expected to use both B30.2(SPRY) domains to
contact the capsid, perhaps via a 2-fold symmetric mode of binding.
The V86M and H87Q changes could potentially disrupt this initial
TRIM5αrh binding. Although the precise higher-order assembly of
TRIM5α is not understood, the formation of TRIM5α hexamers in
solution has been reported (Nepveu-Traversy et al., 2009). It is
possible that alterations of the conformation of the cyclophilin A-
binding loop resulting from the V86M or H87Q changes also disrupt
one or more aspects of the higher-order assembly of TRIM5α dimers.
The binding of cyclophilin A to the capsid contributes to the
potency of HIV-1 restriction by some TRIM5α proteins, including
TRIM5αrh (Berthoux et al., 2005; Stremlau et al., 2006b; Towers et al.,
2003). Decreased binding of the V86M variant to cyclophilin A,nto HIV-1 VLPs was measured. VLPs produced in 239T cells in the presence or absence of
n prepared in PBS. The pellets were analyzed by Western blotting with anti-p24 capsid
to that of the wild-type HIV-1 VLP, is reported in Table 2. The Western blot of one
yp to HIV-1 CA–NC complexes is shown. Binding to the HIV-1 CA–NC complexes was
estern blotting with an anti-p24 antibody (4F6) conjugated to horseradish peroxidase
xidase (Roche). The binding of TRIM5α and TRIMCyp to each mutant CA–NC complex,
typical experiment are shown. The YQ mutant has the Q50Y/T54Q changes in the HIV-1
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TRIM5αrh restriction. First, the P90A mutant, which is markedly
defective in the ability to bind cyclophilin A, replicated less efﬁciently
in TRIM5αrh-expressing cells than the V86M or H87Q mutants; this
was true even in HeLa cells where cyclophilin A binding is not
required by HIV-1 for efﬁcient infection (Li et al., 2009). Second,
although valine 86 and histidine 87 are close to the cyclophilin A-
binding site on the HIV-1 capsid, they do not appear to contribute
signiﬁcantly to the afﬁnity of the cyclophilin-capsid interaction.
Valine 86 does not contact cyclophilin A, being just beyond a van
der Waals contact with alanine 103 of cyclophilin A (Gamble et al.,
1996; Gatanaga et al., 2006). The methionine substitution at capsid
residue 86 might even be expected to increase opportunities for such
contacts with cyclophilin A. Histidine 87 makes no van der Waals
contacts with cyclophilin A; at best, the Nδ1 of histidine 87 is
predicted to form only a non-ideal hydrogen bond with the backbone
carbonyl oxygen of asparagine 71 of cyclophilin A (Gamble et al.,
1996; Gatanaga et al., 2006). Consistent with these structural
observations, the V86M change in the CA–NC complexes resulted in
only very slight decreases in the ability to interact with cyclophilin A
and TRIMCyp, relative to the wild-type CA–NC complexes. Slightly
greater decreases in cyclophilin A and TRIMCyp binding were
observed for the H87Q CA–NC complexes. Apparently, cyclophilin A
and TRIM5αrh bind proximal but distinct structures on the HIV-1
capsid, the former present on the monomer and the latter formed by
quaternary interactions (Dodding et al., 2005; Sebastian and Luban,
2005). In adapting to the TRIM5αrh-expressing cell, HIV-1 apparently
seeks a path that decreases TRIM5α binding while preserving the
greater part of cyclophilin A binding. Both the binding of a restricting
TRIM5α protein and failure to bind cyclophilin A have been shown to
lead to a decrease in the stability of the HIV-1 capsid in the cytosol of
infected cells and a consequent decrease in infectivity (Li et al., 2009;
Stremlau et al., 2006a).
Our results provide some insight into the mechanism whereby
cyclophilin A interaction with the HIV-1 capsid in an infected cell
potentiates TRIM5αrh restriction. Both the G89A and P90A VLPs,
which are deﬁcient in cyclophilin A binding, were inefﬁcient in
competing for restriction factors in PRL cells, compared with the wild-
type HIV-1 VLPs. The deduced decrease in TRIM5αrh binding in these
circumstances may be secondary to the decreased stability, in most
cell types, of HIV-1 capsids that do not bind cyclophilin A (Li et al.,
2009). Changes in the stability of the HIV-1 capsid have been shown to
affect the ability of VLPs to saturate TRIM5α restriction (Shi and
Aiken, 2006). Of note, the G89A and P90A changes exert only minimal
effects on TRIM5αrh binding to CA–NC complexes in vitro; this is
consistent with previous observations that the P90A change only
minimally decreases the in vitro stability of capsid assemblies (Li
et al., 2009). Any slight direct effect of the G89A and P90A changes
on TRIM5αrh binding to the HIV-1 capsid may be ampliﬁed by
the decreased ability of cyclophilin A-binding-deﬁcient capsids to
present a higher-order quaternary structure to TRIM5αrh in the
cytosol.
Future studies will investigate in greater detail the mechanisms by
which HIV-1 crosses species barriers and explore opportunities to use
this information in creating animal models for HIV-1 infection.
Materials and methods
Cell lines
OMK, MK2D, 293T and Cf2Th cells were obtained from the
American Type Culture Collection and maintained in DMEM supple-
mented with 10% fetal bovine serum (DMEM-10). HeLa-CD4 cells
expressing TRIM5αrh have been previously described (Stremlau et al.,
2004) and were maintained in DMEM-10. Primary rhesus lung (PRL)
ﬁbroblasts have been previously described (Hofmann et al., 1999) andwere maintained in DMEM-10. Rhesus monkey peripheral blood
mononuclear cells (PBMC) were isolated from rhesus monkey blood
provided by the New England Primate Research Center (NEPRC).
After isolation with Ficoll-Paque Plus, PBMCs were activated for
3 days with 1 μg of PHA-P and cultured in complete lymphocyte
medium (RPMI-1640 supplemented with 20% FBS, 10% IL-2, 25 mM
HEPES, 2 mM glutamine and antibiotics). The rhesus monkey T-cell
line 221-98 (Alexander et al., 1997), kindly provided by Dr. Ronald
Desrosiers (NEPRC), was maintained in complete lymphocyte
medium.
Cf2Th cell lines expressing TRIM5αrh from rhesus macaques or
TRIMCyp from owlmonkeyswere prepared by transducing Cf2Th cells
with murine leukemia virus (MLV) vectors harboring TRIM5α or
TRIMCyp cDNA. Recombinant TRIM-expressing MLV viruses pseudo-
typed with VSV-G were generated by cotransfecting 293T cells with
4 μg of the pVSV-G plasmid, 4 μg of the pLPCX-TRIM vector plasmid
and 12 μg of the pcPack-B-MLV plasmid using the calcium phosphate
method (Invitrogen). The resulting viral particles were used to
transduce canine Cf2Th cells. Transduced Cf2Th cells were selected
with 5 μg/ml of puromycin.
Virus replication
Replication-competentHIV-1 viruseswere generated by transfecting
20 μg of the pNL4-3 plasmid, which contains an infectious HIV-1NL4-3
provirus (Adachi et al., 1986), into 2×106 293T cells using the calcium
phosphate transfection method (Invitrogen). Forty-eight hours after
transfection, supernatants containing viruses were harvested and
clearedby low-speed centrifugation. The level of virus in the supernatant
was determined by measuring reverse transcriptase (RT), as described
previously (Rho et al., 1981).
Cells were infected with 30,000 RT units of HIV-1NL4-KB9 variants
for 14 h and then washed once with PBS. Every 3 or 4 days, cell
supernatants were removed and used for RT assays. Cells were
trypsinized, diluted 1/10 in fresh medium and replated.
Selected gag mutations were introduced into the HIV-1NL4-KB9
provirus encoding the SEMQ Vif variant (Schrofelbauer et al., 2006).
Infectious viruses were generated and tested for replicative ability as
described above.
Analysis of Gag and Pol sequences
The gag and pol genes of the adapted viruses were ampliﬁed by
polymerase chain reaction (PCR) of genomic DNA isolated from
infected cells with the QIAamp® DNA Blood Mini Kit (QIAGEN). A
4.5-kb fragment containing the full gag-pol sequence was generated
by PCR with PfuUltra™ High-Fidelity DNA polymerase (Stratagene)
and the primers gag-pol-forward: 5′-CTCTCGACGCAGGACTCG-3′ and
gag-pol-reverse: 5′-AAACCAGTCCTTAGCTTTCCTTG-3′. The 4.5 kb frag-
ment was cloned into the pCR®4blunt-TOPO plasmid (Invitrogen).
The inserts from ﬁve individual clones were sequenced to obtain the
consensus sequence in the gag and pol region of the adapted virus.
Site-directed mutagenesis
DNA sequence changes specifying the V86M alteration in capsid,
which was associated with viral adaptation to TRIM5αrh, were
introduced by site-directed mutagenesis using the QuikChange II XL
Site-Directed Mutagenesis protocol (Stratagene) into the
pCMVΔP1ΔenvpA plasmid containing the gag, pol and vif regions of
NL4-3 HIV-1. DNA sequences specifying the previously described
capsid variants H87Q, Q50Y/T54Y, G89A and P90A (Bukovsky et al.,
1997; Franke et al., 1994; Owens et al., 2004) were also introduced by
site-directed mutagenesis into this plasmid for comparison purposes.
The presence of the desiredmutationswas veriﬁed by automated DNA
sequencing.
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The efﬁciency of a single round of HIV-1 infection was measured
by using recombinant reporter viruses expressing ﬁreﬂy luciferase in
place of Nef and pseudotyped with the vesicular stomatitis virus G
glycoprotein (VSV-G). Recombinant luciferase-expressing HIV-1
viruses (Helseth et al., 1990) were generated by transfecting 293T
cells using the calcium phosphate transfection method (Invitrogen)
with 2 μg of the pHCMV-G plasmid expressing the VSV envelope
glycoprotein G, 2 μg of a Rev-expressing plasmid, 4 μg of the
pCMVΔP1ΔenvpA packaging plasmid expressing the corresponding
CA mutant, and 12 μg of an HIV-1 vector plasmid. The HIV-1 vector
plasmid expresses an RNA that can be packaged into virions, reverse
transcribed, and integrated into a target cell, where it encodes ﬁreﬂy
luciferase. Forty-eight hours after transfection, supernatants contain-
ing reporter viruses were harvested and cleared by low-speed
centrifugation. The amounts of virus in the supernatants were
quantiﬁed by measuring RT activity.
Target cells were seeded at a density of 6,000 cells/well in 96-well
luminometer-compatible tissue culture plates. Twenty-four hours
later, medium was changed and different amount of viruses were
added to the cells. After 14 h of incubation, the supernatant was
removed and fresh medium was added. Forty-eight hours later, the
medium was removed and cells were lysed with 30 μl of passive lysis
buffer (Promega). Luciferase activity was measured using an EG&G
Berthold LB 96 V microplate luminometer in accordance with the
luciferase assay system technical bulletin (Promega).
Competition for restriction factors with virus-like particles (VLPs)
For the competition assay with VLPs, the PRL cells were infected
with 2,500 RT units of wild-type luciferase reporter virus in the
presence of 100,000 RT units of virus-like particles lacking a reporter.
These VLPs were generated by co-transfecting 293T cells with 4 μg of
the pHCMV-G plasmid expressing the VSV envelope glycoprotein G,
4 μg of a Rev-expressing plasmid (pRev), and 12 μg of the
pCMVΔP1ΔenvpA packaging plasmid expressing the corresponding
CA mutant. VLPs were concentrated by pelleting through a 20%
sucrose cushion.
Cyclophilin A incorporation into virions
Eight million 293T cells were transfected with 3 μg of pcDNA-
CypA-FLAG, 1 μg of pRev, and 8 μg of pCMVΔP1ΔenvpA harboring
different capsid changes. Forty-eight hours after transfection, super-
natants containing the viral particles were collected and spun at low
speed to remove cell debris. Cleared supernatants were pelleted
through a 20% sucrose cushion prepared in PBS for 2 h at 30,000 rpm
in an SW41 rotor at 4 °C. Pelleted VLPs were resuspended in RT
suspension buffer. Similar amount of VLPs, normalized for RT activity,
were analyzed by SDS-PAGE and Western blotting with anti-p24 and
anti-FLAG antibodies. Western blots were exposed to ﬁlm for time
periods that allowed detection of signals but avoided saturation of the
ﬁlm.
TRIM5αrh and TRIMCyp binding to HIV-1 CA–NC complexes
Puriﬁcation of recombinantly expressed HIV-1 CA–NC protein
from Escherichia coli was carried out as described previously (Ganser
et al., 1999). High-molecular-weight HIV-1–capsid complexes were
assembled using 0.3 mM CA–NC protein and 60 μM (TG)50 DNA
oligonucleotide in a volume of 50 μl of 50 mM Tris–HCl, pH 8.0 and
500 mM NaCl. The reaction was allowed to proceed overnight at 4 °C,
and the assembled CA–NC complexes were stored at 4 °C until
needed.Binding of TRIM5α and TRIMCyp to HIV-1 CA–NC complexes was
measured as previously described (Stremlau et al., 2006a). For a
source of TRIM5 protein, about 4 x 107 Cf2Th cells stably expressing
TRIM5αrh or TRIMCyp were lysed in 1 ml of hypotonic lysis buffer
(10 mM Tris·HCl pH 8.0, 10 mM KCl, 1 mM EDTA) and placed on ice
for 15 min. The cells were frozen/thawed once and the cell debris
were removed by centrifugation at 4 °C for 10 min at maximum speed
(14,000g) in an Eppendorf microfuge. The concentration of NaCl was
adjusted to 150 mM. One hundredmicroliters of the cleared cell lysate
was combinedwith 5 μl of HIV-1 CA–NC complexes from the assembly
reaction. Themixture was incubated for 1 h at room temperature with
gentle mixing. After incubation, the mixture was layered onto a 4.5 ml
70% sucrose cushion (prepared in PBS) and centrifuged at 110,000×g
for 2 h at 4 °C in a Beckman SW55Ti rotor. The pellet was resuspended
in 1x SDS sample buffer and subjected to SDS/PAGE and Western
blotting with an anti-p24 antibody (4F6) conjugated to horseradish
peroxidase (Immunodiagnostics, Inc.) and an anti-HA antibody
(3F10) conjugated to HRP (Roche). Western blots were exposed to
ﬁlm for time periods that allowed detection of signals but avoided
saturation of the ﬁlm.
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